Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 34.17 CNY -11.8% Market Closed
Market Cap: 6B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+24%
Revenue
Forecast
+35%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
Chengdu Easton Biopharmaceuticals Co Ltd

Wall Street analysts forecast Chengdu Easton Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Chengdu Easton Biopharmaceuticals Co Ltd is 42.76 CNY with a low forecast of 42.34 CNY and a high forecast of 44.01 CNY.

Lowest Forecast
Wall Street Target
42.34 CNY
24% Upside
Average Forecast
Wall Street Target
42.76 CNY
25% Upside
Highest Forecast
Wall Street Target
44.01 CNY
29% Upside
Lowest
Price Target
42.34 CNY
24% Upside
Average
Price Target
42.76 CNY
25% Upside
Highest
Price Target
44.01 CNY
29% Upside
Chengdu Easton Biopharmaceuticals Co Ltd Competitors:
Price Targets
600079
Humanwell Healthcare Group Co Ltd
25% Upside
4568
Daiichi Sankyo Co Ltd
75% Upside
SNDL
Sundial Growers Inc
140% Upside
PFE
Pfizer Inc
30% Upside
600079
Humanwell Healthcare Group Co Ltd
25% Upside
4568
Daiichi Sankyo Co Ltd
75% Upside
SNDL
Sundial Growers Inc
140% Upside
PFE
Pfizer Inc
30% Upside
4506
Sumitomo Pharma Co Ltd
1% Downside
IPCALAB
IPCA Laboratories Ltd
21% Upside
C
6919
Caliway Biopharmaceuticals Co Ltd
73% Upside
4523
Eisai Co Ltd
38% Upside

Revenue
Forecast

Revenue Estimate
Chengdu Easton Biopharmaceuticals Co Ltd

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's revenue is 8%. The projected CAGR for the next 3 years is 27%.

8%
Past Growth
27%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Chengdu Easton Biopharmaceuticals Co Ltd

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's operating income is 7%. The projected CAGR for the next 3 years is 22%.

7%
Past Growth
22%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Chengdu Easton Biopharmaceuticals Co Ltd

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's net income is 11%. The projected CAGR for the next 3 years is 27%.

11%
Past Growth
27%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Chengdu Easton Biopharmaceuticals Co Ltd's stock price target?
Price Target
42.76 CNY

According to Wall Street analysts, the average 1-year price target for Chengdu Easton Biopharmaceuticals Co Ltd is 42.76 CNY with a low forecast of 42.34 CNY and a high forecast of 44.01 CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
27%

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's revenue is 8%. The projected CAGR for the next 3 years is 27%.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Operating Income forecast?
Projected CAGR
22%

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's operating income is 7%. The projected CAGR for the next 3 years is 22%.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Net Income forecast?
Projected CAGR
27%

For the last 5 years the compound annual growth rate for Chengdu Easton Biopharmaceuticals Co Ltd's net income is 11%. The projected CAGR for the next 3 years is 27%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.